ABT-888 and Temozolomide for Liver Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Temozolomide

Temozolomide 150 mg/m2/day PO Days 1-5 every 28 days

DRUG

ABT-888

ABT-888 40 mg BID PO Days 1-7 every 28 days

Trial Locations (1)

20007

Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington D.C.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Abbott

INDUSTRY

lead

Georgetown University

OTHER